Vascular biology of eicosanoids and atherogenesis

Domenico Praticò, Jean-Michel Dogné

Research output: Contribution to journalArticlepeer-review


Atherosclerosis is a chronic and progressive inflammatory vascular disease that is characterized by a complex interplay between some components of the bloodstream and the arterial wall. The lipid derivatives eicosanoids have been identified as important mediators that contribute to mechanisms of atherogenesis. Prostaglandins and thromboxane A2 are members of the eicosanoid family synthesized from arachidonic acid by the combined action of cyclooxygenases and prostaglandins and thromboxane A2 synthase. Thromboxane A2, a potent platelet activator and vasoconstrictor and prostacyclin, a platelet inhibitor and vasodilator, are the most important in the development of cardiovascular diseases. Several pro-atherogenic biological effects have also been attributed to isoprostanes, a class of eicosanoid isomers formed via a free radical-mediated oxidation of fatty acids esterified in membrane phospholipids. Both groups of lipids manifest their biological activities by binding to specific receptors in target cells. In this article, we will describe the biological roles of prostacyclin, thromboxane A2 and isoprostanes in atherogenesis and discuss the latest pharmacological studies assessing the therapeutic effects of drugs that specifically target their biosynthesis and/or biological activities on vascular inflammation and atherosclerotic lesion development.
Original languageEnglish
Pages (from-to)1079-89
Number of pages11
JournalExpert Review of Cardiovascular Therapy
Issue number9
Publication statusPublished - Sept 2009


  • Animals
  • Atherosclerosis
  • Cardiovascular Agents
  • Cyclooxygenase Inhibitors
  • Drug Delivery Systems
  • Eicosanoids
  • Epoprostenol
  • Humans
  • Inflammation
  • Isoprostanes
  • Thromboxane A2


Dive into the research topics of 'Vascular biology of eicosanoids and atherogenesis'. Together they form a unique fingerprint.

Cite this